399 related articles for article (PubMed ID: 28661412)
1. Risk of new-onset diabetes mellitus in primary aldosteronism: a population study over 5 years.
Wu VC; Chueh SJ; Chen L; Chang CH; Hu YH; Lin YH; Wu KD; Yang WS;
J Hypertens; 2017 Aug; 35(8):1698-1708. PubMed ID: 28661412
[TBL] [Abstract][Full Text] [Related]
2. Risk of new-onset autoimmune diseases in primary aldosteronism: a nation-wide population-based study.
Er LK; Chen L; Tsai YC; Lin YH; Huang WC; Chang CC; Lu CC; Huang KH; Chueh JS; Wu KD; Wu VC;
J Hypertens; 2020 Apr; 38(4):745-754. PubMed ID: 31764584
[TBL] [Abstract][Full Text] [Related]
3. Surgery decreases the long-term incident stroke risk in patients with primary aldosteronism.
Chang YH; Chung SD; Wu CH; Chueh JS; Chen L; Lin PC; Lin YH; Huang KH; Wu VC; Chu TS;
Surgery; 2020 Feb; 167(2):367-377. PubMed ID: 31676114
[TBL] [Abstract][Full Text] [Related]
4. Time-Dependent Risk of Atrial Fibrillation in Patients With Primary Aldosteronism After Medical or Surgical Treatment Initiation.
Kim KJ; Hong N; Yu MH; Lee H; Lee S; Lim JS; Rhee Y
Hypertension; 2021 Jun; 77(6):1964-1973. PubMed ID: 33866798
[TBL] [Abstract][Full Text] [Related]
5. [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].
Szücs N; Gláz E; Varga I; Tóth M; Kiss R; Patócs A; Jakab C; Perner F; Járay J; Horányi J; Dabasi G; Molnár F; Major L; Füto L; Rácz K; Tulassay Z
Orv Hetil; 2006 Jan; 147(2):51-9. PubMed ID: 16509213
[TBL] [Abstract][Full Text] [Related]
6. Long term outcome of Aldosteronism after target treatments.
Wu VC; Wang SM; Chang CH; Hu YH; Lin LY; Lin YH; Chueh SC; Chen L; Wu KD
Sci Rep; 2016 Sep; 6():32103. PubMed ID: 27586402
[TBL] [Abstract][Full Text] [Related]
7. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study.
Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
Lancet Diabetes Endocrinol; 2018 Jan; 6(1):51-59. PubMed ID: 29129576
[TBL] [Abstract][Full Text] [Related]
8. Influence of Different Treatment Strategies on New-Onset Atrial Fibrillation Among Patients With Primary Aldosteronism: A Nationwide Longitudinal Cohort-Based Study.
Pan CT; Liao CW; Tsai CH; Chen ZW; Chen L; Hung CS; Liu YC; Lin PC; Chang CC; Chang YY; Wu VC; Lin YH;
J Am Heart Assoc; 2020 Mar; 9(5):e013699. PubMed ID: 32070205
[TBL] [Abstract][Full Text] [Related]
9. Risk of sepsis in patients with primary aldosteronism.
Chan CK; Hu YH; Chen L; Chang CC; Lin YF; Lai TS; Huang KH; Lin YH; Wu VC; Wu KD;
Crit Care; 2018 Nov; 22(1):313. PubMed ID: 30463626
[TBL] [Abstract][Full Text] [Related]
10. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism.
Catena C; Colussi G; Lapenna R; Nadalini E; Chiuch A; Gianfagna P; Sechi LA
Hypertension; 2007 Nov; 50(5):911-8. PubMed ID: 17893375
[TBL] [Abstract][Full Text] [Related]
11. Renal Outcomes in Medically and Surgically Treated Primary Aldosteronism.
Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
Hypertension; 2018 Sep; 72(3):658-666. PubMed ID: 29987110
[TBL] [Abstract][Full Text] [Related]
12. Long-term mortality and cardiovascular events in patients with unilateral primary aldosteronism after targeted treatments.
Wu VC; Wang SM; Huang KH; Tsai YC; Chan CK; Yang SY; Lin LY; Chang CC; Lu CC; Lin YH; Chen YM; Chueh JS
Eur J Endocrinol; 2021 Dec; 186(2):195-205. PubMed ID: 34851859
[TBL] [Abstract][Full Text] [Related]
13. Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism.
Pecori A; Buffolo F; Burrello J; Mengozzi G; Rumbolo F; Avataneo V; D'Avolio A; Rabbia F; Bertello C; Veglio F; Mulatero P; Monticone S
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3655-e3664. PubMed ID: 33942084
[TBL] [Abstract][Full Text] [Related]
14. Systematic review of the clinical outcomes of mineralocorticoid receptor antagonist treatment versus adrenalectomy in patients with primary aldosteronism.
Satoh M; Maruhashi T; Yoshida Y; Shibata H
Hypertens Res; 2019 Jun; 42(6):817-824. PubMed ID: 30948836
[TBL] [Abstract][Full Text] [Related]
15. Long-term renal outcomes in patients with primary aldosteronism.
Sechi LA; Novello M; Lapenna R; Baroselli S; Nadalini E; Colussi GL; Catena C
JAMA; 2006 Jun; 295(22):2638-45. PubMed ID: 16772627
[TBL] [Abstract][Full Text] [Related]
16. Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism.
Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
JAMA Cardiol; 2018 Aug; 3(8):768-774. PubMed ID: 30027227
[TBL] [Abstract][Full Text] [Related]
17. New-onset diabetes mellitus risk associated with concurrent autonomous cortisol secretion in patients with primary aldosteronism.
Wu VC; Chan CK; Wu WC; Peng KY; Chang YS; Yeh FY; Chiang JY; Lee YJ; Liu KL; Wang SM; Lin YH; Chueh JS;
Hypertens Res; 2023 Feb; 46(2):445-455. PubMed ID: 36481967
[TBL] [Abstract][Full Text] [Related]
18. Oxidative stress in patients affected by primary aldosteronism.
Petramala L; Pignatelli P; Carnevale R; Zinnamosca L; Marinelli C; Settevendemmie A; Concistrè A; Tonnarini G; De Toma G; Violi F; Letizia C
J Hypertens; 2014 Oct; 32(10):2022-9; discussion 2029. PubMed ID: 24979305
[TBL] [Abstract][Full Text] [Related]
19. Long-term effect of specific treatment of primary aldosteronism on carotid intima-media thickness.
Holaj R; Rosa J; Zelinka T; Štrauch B; Petrák O; Indra T; Šomlóová Z; Michalský D; Novák K; Wichterle D; Widimský J
J Hypertens; 2015 Apr; 33(4):874-82; discussion 882. PubMed ID: 25490707
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular outcomes in patients with primary aldosteronism after treatment.
Catena C; Colussi G; Nadalini E; Chiuch A; Baroselli S; Lapenna R; Sechi LA
Arch Intern Med; 2008 Jan; 168(1):80-5. PubMed ID: 18195199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
